
Pharvaris N.V (PHVS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Operating Income
-47.4M
Net Income
-53.4M
EPS (Diluted)
$-0.83
Balance Sheet Metrics
Total Assets
246.2M
Total Liabilities
29.9M
Shareholders Equity
216.3M
Debt to Equity
0.14
Cash Flow Metrics
Operating Cash Flow
-44.6M
Free Cash Flow
-35.2M
Revenue & Profitability Trend
Pharvaris N.V Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 115.6M | 65.6M | 57.4M | 35.8M | 19.5M |
Selling, General & Administrative | 55.3M | 31.3M | 29.3M | 18.3M | 5.5M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 170.9M | 96.9M | 86.7M | 54.1M | 25.0M |
Operating Income | -170.9M | -96.9M | -86.7M | -54.1M | -25.0M |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | - | - | 16.1K | 267.5K | 92.5K |
Other Non-Operating Income | 9.2M | -3.1M | 11.1M | 11.8M | -963.7K |
Pre-tax Income | -155.3M | -99.8M | -75.7M | -42.7M | -26.1M |
Income Tax | 2.1M | 1.0M | 679.1K | 70.1K | -83.3K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -157.5M | -100.9M | -76.3M | -42.7M | -26.0M |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -179.8M | -93.5M | -97.7M | -65.8M | -25.0M |
EPS (Basic) | $-2.48 | $-2.63 | $-2.27 | $-1.40 | $-0.85 |
EPS (Diluted) | $-2.48 | $-2.63 | $-2.27 | $-1.40 | $-0.85 |
Basic Shares Outstanding | 63378528 | 34986122 | 32759089 | 29663160 | 29767891 |
Diluted Shares Outstanding | 63378528 | 34986122 | 32759089 | 29663160 | 29767891 |
Income Statement Trend
Pharvaris N.V Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 329.4M | 391.2M | 161.8M | 209.4M | 98.6M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | - | - | 0 | 8.5K | 0 |
Inventory | - | - | - | - | - |
Other Current Assets | - | 620.8K | 582.6K | 5.7K | 1.2M |
Total Current Assets | 339.6M | 397.9M | 166.8M | 211.6M | 101.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.0M | 580.9K | 692.0K | 378.0K | 56.5K |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 556.5K | 387.5K | 259.8K | 172.1K | 99.3K |
Total Non-Current Assets | 2.3M | 843.1K | 886.2K | 523.4K | 147.8K |
Total Assets | 341.8M | 398.7M | 167.7M | 212.1M | 101.1M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 5.4M | 2.9M | 6.0M | 2.1M | 656.4K |
Short-term Debt | 261.0K | 195.3K | 187.4K | 99.4K | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 27.0M | 14.6M | 18.2M | 7.0M | 5.3M |
Non-Current Liabilities | |||||
Long-term Debt | 749.7K | 43.6K | 249.4K | 150.8K | 0 |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | -1 | - |
Total Non-Current Liabilities | 749.7K | 43.6K | 249.4K | 150.8K | 0 |
Total Liabilities | 27.7M | 14.6M | 18.5M | 7.1M | 5.3M |
Equity | |||||
Common Stock | 7.7M | 6.3M | 4.1M | 4.0M | 235.7K |
Retained Earnings | -471.9M | -265.9M | -164.2M | -87.6M | -44.5M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 314.1M | 384.0M | 149.3M | 205.0M | 95.8M |
Key Metrics | |||||
Total Debt | 1.0M | 238.9K | 436.8K | 250.2K | 0 |
Working Capital | 312.6M | 383.2M | 148.6M | 204.6M | 95.6M |
Balance Sheet Composition
Pharvaris N.V Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -155.3M | -99.8M | -75.7M | -42.7M | -26.1M |
Depreciation & Amortization | 316.3K | 257.6K | 152.9K | 77.4K | 7.4K |
Stock-Based Compensation | 19.0M | 10.7M | 11.3M | 8.2M | 1.6M |
Working Capital Changes | -200.2K | -994.9K | -2.2M | 109.4K | -851.9K |
Operating Cash Flow | -142.6M | -90.1M | -66.3M | -34.0M | -25.2M |
Investing Activities | |||||
Capital Expenditures | -631.3K | -90.0K | -124.3K | -130.0K | -43.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -631.3K | -90.0K | -124.3K | -130.0K | -43.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -187.3K | -220.5K | -119.5K | 0 | 0 |
Financing Cash Flow | 3.1M | 325.4M | 8.7M | 143.7M | 101.2M |
Free Cash Flow | -141.6M | -93.1M | -67.3M | -44.7M | -21.5M |
Net Change in Cash | -140.1M | 235.2M | -57.8M | 109.5M | 75.9M |
Cash Flow Trend
Pharvaris N.V Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.35
Forward P/E
-7.61
Price to Book
6.89
PEG Ratio
-0.18
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-65.09%
Return on Assets
-36.85%
Financial Health
Current Ratio
8.33
Debt to Equity
0.34
Beta
-2.80
Per Share Data
EPS (TTM)
$-3.62
Book Value per Share
$3.37
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
phvs | 1.5B | -9.35 | 6.89 | -65.09% | 0.00% | 0.34 |
Vertex | 101.2B | 28.08 | 5.89 | 22.77% | 31.86% | 8.89 |
Alnylam | 61.1B | -213.71 | 244.95 | -257.83% | -12.96% | 1,093.31 |
Adaptive | 1.9B | -11.68 | 10.68 | -57.60% | -59.07% | 121.39 |
Dyne Therapeutics | 1.9B | -3.90 | 2.63 | -61.32% | 0.00% | 21.19 |
Harmony Biosciences | 1.9B | 10.45 | 2.41 | 27.58% | 23.42% | 22.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.